Customize your JAMA Network experience by selecting one or more topics from the list below.
In several studies, antiretroviral drugs (principally zidovudine) have been used with success in the treatment of myelopathy associated with human T-lymphotrophic virus 1 (HTLV-1) (tropical spastic paraparesis–HTLV-1–associated myelopathy). The retrovirus HTLV-1 has been implicated as a causative agent of Sjögren syndrome (SS) in clinical reports and murine experiments. Moreover, a recognized complication of primary SS is a myelopathy, which has been shown in case reports to respond to immunosuppressive treatment.
To describe a patient with a rapidly progressive, extensive myelopathy with evidence of HTLV-1 infection and SS (probably secondary to HTLV-1) in whom we achieved spectacular therapeutic success using combined immunosuppressive and antiviral therapy.
A young Haitian woman diagnosed with HTLV-1 and SS developed extensive myelopathy leading to severe disability.
Main Outcome Measures
Clinical and radiological improvement.
Spectacular radiological and clinical recovery as well as stabilization were achieved with combined antiviral and immunosuppressant treatment. Follow-up at 2 years showed no signs of relapse.
Both tropical spastic paraparesis–HTLV-1–associated myelopathy and Sjögren myelopathy are potentially very disabling. Rapidly progressive myelopathy secondary to SS necessitates the introduction of immunosuppressant therapies. The presence of HTLV-1 may confer the necessity to add antiviral therapy.
Pot C, Chizzolini C, Vokatch N, et al. Combined Antiviral-Immunosuppressive Treatment in Human T-Lymphotrophic Virus 1–Sjögren–Associated Myelopathy. Arch Neurol. 2006;63(9):1318–1320. doi:10.1001/archneur.63.9.1318
Create a personal account or sign in to: